Gene therapy for relapsing-remitting multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new gene therapy called GT802 for people with relapsing-remitting MS that hasn't responded to usual treatments. The goal is to see if it can control the disease safely and effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have relapsing-remitting multiple sclerosis (MS) that has not improved with standard treatments.
- You must have stopped other MS treatments for at least 4 weeks (or 5 half-lives) before starting the study drug.
- Any side effects from previous treatments must be stable and mild (like hair loss, which is okay).
- Your blood tests need to meet certain levels, and you must be willing to avoid pregnancy or fathering a child for at least 1 year after the infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cell therapy called STAR-T to see if it is safe and helps people with multiple sclerosis (MS). The therapy uses immune cells that are grown in the lab and put back into your body to potentially slow or stop MS progression.
This trial tests a new cell therapy called SYS6020 for people with multiple sclerosis that has not improved with standard treatments. The goal is to see if it can slow or stop the disease and improve symptoms.
This trial tests a new antibody drug (GT719) for adults with autoimmune neurological diseases that came back or did not get better with standard treatment. It looks at how safe the drug is and how well it works.
This early phase trial tests a new treatment called GC012F for people with multiple sclerosis. It aims to see how safe and tolerable it is, and may offer a new option for those whose current treatments are not working well enough.
This trial tests a new cell therapy called YTB323 for people with relapsing multiple sclerosis (RMS) that is still active despite strong treatments. The treatment aims to reset the immune system to stop attacks on nerves.
This trial tests a new gene therapy, LVIVO-TaVec200, for people with multiple myeloma that has returned or not responded to other treatments. The goal is to see if it can help control the cancer.
Hear when a new Multiple Sclerosis (MS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.